Literature DB >> 10567047

Mutations of calpain 3 gene in patients with sporadic limb-girdle muscular dystrophy in Japan.

N Minami1, I Nishino, O Kobayashi, K Ikezoe, Y Goto, I Nonaka.   

Abstract

Mutations of the calpain 3 gene, an intracellular calcium-activated neutral protease, is one of the causes of limb-girdle muscular dystrophy (LGMD). We examined 14 Japanese patients with sporadic LGMD for calpain 3 mutations, and found four mutations in five patients. Three (R461C, D707G and R147P) were novel missense mutations, and one was a splice-site mutation (801+1g-->a) resulting in skipping of exons 4 and 5. Of the five patients, three patients with homozygous missense mutations showed later onset and slower progression than the other two patients with an exon skipping or mRNA loss of unknown cause. It would appear that the occurrence of calpain 3 gene mutations in sporadic LGMD in Japan may be quite high since all five patients with mutations in this gene were among the 14 patients without apparent family history, an incidence of 36%. These findings also suggest that calpain 3 deficiency occurs in both sporadic and familial LGMD and that direct analysis of the calpain 3 gene may be useful in the definitive diagnosis not only of the 15q-linked familial but also of sporadic cases of LGMD.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10567047     DOI: 10.1016/s0022-510x(99)00245-2

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  8 in total

1.  Mutations in calpain 3 associated with limb girdle muscular dystrophy: analysis by molecular modeling and by mutation in m-calpain.

Authors:  Z Jia; V Petrounevitch; A Wong; T Moldoveanu; P L Davies; J S Elce; J S Beckmann
Journal:  Biophys J       Date:  2001-06       Impact factor: 4.033

2.  Order of intron removal influences multiple splice outcomes, including a two-exon skip, in a COL5A1 acceptor-site mutation that results in abnormal pro-alpha1(V) N-propeptides and Ehlers-Danlos syndrome type I.

Authors:  Kazuhiko Takahara; Ulrike Schwarze; Yasutada Imamura; Guy G Hoffman; Helga Toriello; Lynne T Smith; Peter H Byers; Daniel S Greenspan
Journal:  Am J Hum Genet       Date:  2002-07-17       Impact factor: 11.025

3.  Impaired regeneration in LGMD2A supported by increased PAX7-positive satellite cell content and muscle-specific microrna dysregulation.

Authors:  Xiomara Q Rosales; Vinod Malik; Amita Sneh; Lei Chen; Sarah Lewis; Janaiah Kota; Julie M Gastier-Foster; Caroline Astbury; Rob Pyatt; Shalini Reshmi; Louise R Rodino-Klapac; K Reed Clark; Jerry R Mendell; Zarife Sahenk
Journal:  Muscle Nerve       Date:  2013-03-29       Impact factor: 3.217

4.  Identification of a Novel Deep Intronic Mutation in CAPN3 Presenting a Promising Target for Therapeutic Splice Modulation.

Authors:  Ying Hu; Payam Mohassel; Sandra Donkervoort; Pomi Yun; Véronique Bolduc; Daniel Ezzo; Jahannaz Dastgir; Jamie L Marshall; Monkol Lek; Daniel G MacArthur; A Reghan Foley; Carsten G Bönnemann
Journal:  J Neuromuscul Dis       Date:  2019

Review 5.  Limb-girdle Muscular Dystrophies in India: A Review.

Authors:  Satish V Khadilkar; Hinaben Dayalal Faldu; Sarika Bapuso Patil; Rakesh Singh
Journal:  Ann Indian Acad Neurol       Date:  2017 Apr-Jun       Impact factor: 1.383

6.  Mutations of CAPN3 in Korean patients with limb-girdle muscular dystrophy.

Authors:  Jin-Hong Shin; Hyang-Suk Kim; Chang-Hoon Lee; Cheol-Min Kim; Kyu-Hyun Park; Dae-Seong Kim
Journal:  J Korean Med Sci       Date:  2007-06       Impact factor: 2.153

7.  Loss of calpain-3 autocatalytic activity in LGMD2A patients with normal protein expression.

Authors:  Marina Fanin; Anna Chiara Nascimbeni; Luigi Fulizio; Carlo Pietro Trevisan; Marija Meznaric-Petrusa; Corrado Angelini
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

8.  How to tackle the diagnosis of limb-girdle muscular dystrophy 2A.

Authors:  Marina Fanin; Anna Chiara Nascimbeni; Elisabetta Tasca; Corrado Angelini
Journal:  Eur J Hum Genet       Date:  2008-10-15       Impact factor: 4.246

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.